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Abstract: Natural and synthetic xanthone derivatives are well-known for their ability to act 
as antioxidants and/or enzyme inhibitors. This paper aims to present a successful synthetic 
methodology towards xanthenedione derivatives and the study of their aromatization to 
xanthones. Additionally their ability to reduce Fe(III), to scavenge DPPH radicals and to 
inhibit AChE was evaluated. The results demonstrated that xanthenedione derivative 5e, 
bearing a catechol unit, showed higher reduction capacity than BHT and similar to 
quercetin, strong DPPH scavenging activity (EC50 = 3.79 ± 0.06 µM) and it was also  
showed to be a potent AChEI (IC50 = 31.0 ± 0.09 µM) when compared to galantamine 
(IC50 = 211.8 ± 9.5 µM). 
Keywords: xanthene-1,9(2H)-diones; scavenging activity; reduction power; 
acetylcholinesterase inhibitors; xanthones; 3-cinnamoyl-5-hydroxy-2-styrylchromones 
 
1. Introduction 
Antioxidants are necessary to control degenerative reactions produced by reactive oxygen and 
nitrogen species. These species are involved in several ailments including cancer, heart diseases and 
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apparently Alzheimer’s disease (AD) [1]. Alzheimer’s disease remains a mystery and a source of 
several discussions [2], but there is evidence that it is related with oxidative stress [3], as well as with 
cholinesterase activity [4]. Although the current therapy used for AD is based on acetylcholinesterase 
(AChE) inhibitors [5,6] it seems that other possibilities cannot be rejected. Thus antioxidants that are 
considered as a prime target for potential chemoprevention of several pathologies may also become 
important phytochemicals against degenerative diseases such as AD. 
The alkaloid galantamine (1, Figure 1) is used clinically in early stages of AD, nevertheless  
non-alkaloidal AChE inhibitors are being discovered, including xanthone derivatives [6,7]. Variations 
in the hydroxylation and methoxylation pattern seem to be important for their activity, as well as extra 
rings and a hydrophobic side chain as in 2 (Figure 1) [7]. As far as we are aware there are no reports on 
AChE inhibitors bearing a xanthenedione type structure, but we can find in the literature examples of 
derivatives that showed DPPH radical scavenging activity [8]. Xanthenedione derivatives are not 
widespread in Nature but their synthesis still is a hot topic. Several approaches for the synthesis of 
xanthenediones have been reported, although most of them were strategies towards xanthene-1,8-
diones [9]. Xanthene-1,9-diones were less reported [10], but as a part of our ongoing efforts to develop 
new biologically active compounds we developed a very interesting and efficient strategy towards 
these type of derivatives [11]. Based on this earlier discovery we became interested in the evaluation of 
the obtained xanthene-1,9-dione derivatives as antioxidant and acetylcholinesterase inhibitors as well 
as on their aromatization to xanthone derivatives. 
Figure 1. AChE inhibitors. 
 
2. Results and Discussion 
2.1. Chemistry 
For the synthesis of xanthene-1,9(2H)-dione derivatives a nice portfolio of suitable reactions was 
developed (Scheme 1). The most important approach was the highly efficient Baker-Venkataraman 
rearrangement under microwave irradiation of (E,E)-2-acetyl-1,3-phenylenebis(3-phenylacrylate) 
derivatives 3 to (E,E)-3-cinnamoyl-5-hydroxy-2-styrylchromones 4. Compounds 3 and 4 were 
previously obtained in good overall yields and were also well characterized [12]. However the 
application of microwave irradiation is not only a less energetically expensive procedure, but it also  
presents a very important beneficial effect, the shortening of the reaction time. The cyclization in the 
presence of the Lewis acid boron tribromide as catalyst of (E,E)-3-cinnamoyl-5-hydroxy-2-
styrylchromones 4 to (E)-3-aryl-4-benzylidene-8-hydroxy-3,4 dihydro-1H-xanthene-1,9(2H)-diones 5 
was also very efficient and constitutes an extremely simple synthetic procedure. This protocol works 
nicely for several derivatives, but its application in the cyclization of (E,E)-3-cinnamoyl-5-hydroxy-2-
styrylchromones 4 bearing electron withdrawing groups is less efficient. The yields in the formation of 
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compounds 5d and 5f were lower and more degradation products were observed. Another interesting 
result was the fact that when (E,E)-3-cinnamoyl-5-hydroxy-2-styrylchromone (4g) was used as starting 
material, (E)-1,13-dihydroxy-6-(2-hydroxybenzylidene)-6,7-dihydro-7,13-methanobenzo[7,8]oxocino 
[4,3-b]chromen-14(13H)-one (6) was obtained as main product and 6,8-dihydroxy-13-(2-hydroxyphenyl) 
chromeno[4,3-c]xanthen-7(13H)-one (7) as a by-product (Scheme 1). These results can be explained 
by an intramolecular cyclization to a hemiketal compound [Scheme 2, path (a) to compound 6], and 
other intramolecular cyclization followed by aromatization to the xanthone 7 [Scheme 2, path (b)]. 
Scheme 1. Synthesis of xanthene-1,9(2H)-diones. 
  
Scheme 2. Proposed mechanism. 
 
The isolation of xanthone 7 and our ongoing interest in the synthesis of new xanthone derivatives, 
in particular xanthones bearing aromatic rings attached to the central core [13] prompted us to  
study the aromatization of xanthene-1,9(2H)-diones 5. (E)-8-Hydroxy-4-(4-methylbenzylidene)-3-(4-
methylphenyl)-3,4-dihydro-1H-xanthene-1,9(2H)-dione (5b) was used to find the optimal conditions 
for the required aromatization. In the first attempts, the reactions with 5b were performed under acidic 
conditions to induce the enolization between carbons C-1 and C-2 and the 1,3-shift of H-3 to C-7". 
Considering that strong or weak acids, at room temperature or heating using classical heating 
conditions or microwave irradiation did not work, the starting material being recovered, it was decided 
to attempt basic catalysis. After testing several bases, only DBU and LiHMDS, under the conditions 
indicated in Table 1 (entry 1 and 2), were able to aromatize the xanthenedione 5b to the desired 
xanthone 8b (Scheme 3). However, as can be understood from Table 1 the results were not good so it 
was decided to attempt oxidative conditions. Several oxidizing reagents and/or conditions for the 
Molecules 2014, 19 8320 
 
 
oxidation of xanthenedione 5b were examined, and it was found that although the benzylic carbon is 
also very reactive the aromatization can be accomplished, and several new xanthone derivatives were 
isolated (Scheme 3). For instance, xanthone 9b was obtained in the oxidation of 5b with DDQ in 1,2,4-
trichlorobenzene (TCB) (Table 1, entry 3), although using dry TCB and molecular sieves an interesting 
cyclization to xanthone 10b occurred (Table 1, entry 4). Under the same conditions at lower 
temperature the result was also unexpected (Table 1, entry 5), although it is known that under DDQ 
oxidation conditions several intramolecular transformations can occur [14]. The oxidation of 5b was 
also attempted with the softer oxidizing reagent chloranil, which did not work as well (Table 1, entry 6) 
and a new xanthone 12b was obtained (Scheme 3). We tested even milder conditions (Pd/C, Table 1, 
entry 7) which gave the desired xanthone 8b in low yields together with xanthones 9b and 11b. The 
results, although were not the expected ones, are interesting. One can conclude that xanthenediones 5 
can became useful synthons towards new xanthone derivatives. 
Table 1. Optimization of the aromatization conditions. 
Entry Catalyst Experimental conditions a Obtained compounds b (%) 
1 1.2 equiv DBU MW (100 °C, 10 min), DMSO 8b (18%) 
2 LiHMDS Classical heating (80 °C), toluene 8b (<5%) 
3 2 equiv DDQ MW (170 °C, 30 min), TCB 9b (28%) 
4 1.5 equiv DDQ MW (170 °C, 30 min), dry TCB, molecular sieves 10b (52%) 
5 1.3 equiv DDQ MW (100 °C, 30 min), dry TCB,  molecular sieves 
9b (15%) 
11b (30%) 
6 2 equiv ChA MW (170 °C, 30 min), dry TCB,  molecular sieves 
9b (10%) 
12b (34%) 
7 Pd/C (1:1 w/w) Classical heating(reflux toluene) 
8b (15%); 9b (22%) 
11b (25%) 
a Only the experimental conditions affording new compounds are described and only the best yields are 
mentioned; b Only the major compounds are indicated and starting compound was recovered in all attempts; 
TCB = 1,2,4-trichlorobenzene. 
Scheme 3. Compounds obtained in the aromatization study of xanthenedione 5b. 
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2.2. Nuclear Magnetic Resonance Spectroscopy 
The NMR characterization of bis(3-phenylacrylate) derivatives 3, 3-cinnamoyl-5-hydroxy-2-
styrylchromones 4 and xanthene-1,9(2H)-diones 5 was previously discussed [11,12] therefore here 
only the characterization of the new derivatives will be reported. 
At the first glances the 1H-NMR spectrum of compound 6 seems to indicate the presence of another 
xanthenedione derivative. But a carefully analysis showed that H-2 protons are equivalent and appear 
as a doublet at δ 2.56 ppm with a coupling constant (J = 3.1 Hz) due to the coupling with proton H-3, 
which appears as a triplet at δ 4.05 ppm. Another interesting feature is the chemical shift of  
the H-7'' proton which appears as singlet at δ 7.27 ppm. In the 13C-NMR spectrum instead of two 
carbonyl carbons at δ ~191 and ~180 ppm like in the case xanthenediones just one signal due to a 
carbonyl carbon resonance is observed at δ 183.2 ppm. These data are considerably different from 
those of xanthenediones and suggested a different structure. The connectivities found in the HMBC 
spectrum allowed assigning the quaternary carbon resonances and confirming the assignments of some  
proton-bearing carbons (Figure 2a). Moreover, the NOESY experiment led to confirm the proposed 
structure, namely the NOE effects between the signals of H-7'' and H-3 and of H-6 and H-6''  
(Figure 2b). 
Figure 2. Main HMBC and NOESY correlations. 
 
The obtained xanthone derivatives 7 and 8b–12b have in common the central nucleus that presents 
characteristic 1H and 13C-NMR spectra. Besides these typical protons and carbon resonances the 
presence of the aromatic rings A and E can be highlighted by: (i) the singlet due to the H-2 proton 
resonance at δ 6.79–7.26 ppm; (ii) the two signals due to hydroxyl group proton, as singlets at δ  
11.70–11.90 ppm (9-OH) and at δ 11.78–12.22 ppm (1-OH); (iii) the carbonyl carbon resonance at δ 
185.3–186.1 ppm; (iv) the connectivities found in the HMBC spectra confirming this structural motif 
(Figure 2c). The rest of the structures present two types of substitution, xanthones 7, 10b and 12b with 
an extra ring linking rings B and D and xanthones 8b, 9b and 11b with unlinked substituents at 
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carbons C-3 and C-4. The p-tolyl group at carbon C-3 presents the characteristic 1H-NMR signals of a 
para substituted aromatic ring and the most distinguishable signals are: (i) the singlet at δ 4.10 ppm, 
due to the resonance of the benzylic CH2 protons of 8b; (ii) the doublet at δ 6.02 ppm, due to the H-7" 
proton resonance proton and the broad singlet at δ 2.98 ppm, due to the 7"-hydroxyl group of xanthone 
11b. The main feature of the 13C-NMR spectrum of xanthone 9b is the carbonyl carbon resonance at δ 
194.0 ppm. The HMBC connectivities allowed assigning and/or confirming all carbon resonances and 
confirming the proposed structures as depicted in Scheme 3. 
The important signals in the NMR spectra of xanthone 7 are the singlet at δ 7.14 ppm assigned to a 
proton linked to a carbon that resonates at δ 70.9 ppm and that in the HMBC spectrum showed 
connectivity with the H-7" proton (Figure 2d). In xanthones 10b and 12b the disappearance of an 
aromatic proton and the consequently change in the NMR pattern of the D ring it is noticeable. In these 
compounds, it consists in three characteristic signals, a broad singlet or doublet with a meta coupling 
constant due to the H-3' proton (δ ~7.1 ppm), a doublet due to the H-6' proton (δ ~7.6 ppm) and a 
double doublet assigned to H-5' (δ ~7.2 ppm). The confirmation of the five member ring was provided 
by the HMBC spectrum (Figure 2e), which showed connectivities between H-3' and C-7" only possible 
in the proposed structures. 
2.3. Reducing Power and Radical Scavenging Activity 
As was raised in the Introduction there are several diseases and symptoms directly related to 
oxidative stress, such as: atherosclerosis, Alzheimer’s, cancer, the aging process and central nervous 
system degeneration [15]. Antioxidant compounds can become important in preventing and/or treating 
these diseases. In order to evaluate the antioxidant activity of xanthenediones 5, we tested their ability 
to scavenge DPPH radicals and to reduce iron(III) and the results are presented in Figure 3 and Table 2.  
Figure 3. Reducing activity of xanthenediones 5c,e. 
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Table 2. Radical scavenging activity and acetylcholinesterase inhibitory effect of 
xanthenediones (5). 
Compounds 
Radical Scavenging Activity
Anti-AChE IC50 c (µM ± SD, n = 4) EC50 a (µM ± SD) AE b 
5a nd nd >381 
5b nd nd >355 
5c >552 nd 41.1 ± 6.1 
5d nd nd >325 
5e 3.79 ± 0.06 0.026 31.0 ± 0.09 
5f nd nd >325 
Trolox 18.7 ± 0.65 0.011 - 
Quercetin 5.97 ± 0.11 0.0042 - 
Galantamine - - 211.8 ± 9.5 
a The required concentration of the compound to reduce the DPPH• concentration to 50%; b The antiradical 
efficiency (AE = 1/(EC50 × TEC50); TEC50 the time required to reach the steady state for the EC50; c The 
required concentration of the compound to inhibit 50% of acetylcholinesterase activity; nd not determined. 
Reducing power is the manifestation of the electron donating capacity of a compound and can be 
associated with its antioxidant activity [16] and also with structural features such as ortho-dihydroxyl 
groups or hydroxyl groups that can form a hydrogen bond with a carbonyl group. Thus, 
xanthenediones 5a, 5c and 5e were tested using the potassium ferricyanide reduction method [17]. 
BHT and quercetin were used as references due to their well-known antioxidant properties. Quercetin 
has an additional significance, as it is structurally more similar to the tested compounds. The 
compounds were tested at four concentrations, and naturally the reducing ability increased with 
concentration (Figure 3). Xanthenediones 5a and 5c did not significantly reduce ferric ion. 
Xanthenedione 5e was able not only to reduce considerably the ferric ion, but was also more efficient 
than BHT and similar to quercetin (Figure 3). These results confirm that a catechol moiety in a 
molecule is important for the reducing power activity. Considering the above mentioned conclusions 
and the fact that xanthenedione 5c did not violate any of the Lipinski’s ‘rule of five’ (Table 3) we 
decided to test also its radical scavenging activity (Table 2). However the solubility of xanthenedione 5c 
did not allow an EC50 calculation. At the maximum concentration at which xanthenedione 5c is soluble 
(552 µM), the DPPH quenched was just 36%. 
2.4. Acetylcholinesterase Inhibitory Activity (Anti-AChE) 
Acetylcholinesterase (AChE) plays a very important role in nerve transmission, as an adhesion 
protein, as a bone matrix protein, in neurite growth and in the production of amyloid fibrils, found in 
the brain cells of patients with Alzheimer’s disease [6]. Inhibition of AChE will, therefore, allow the 
stimulatory activity of acetylcholine (ACh), which appears to be associated with cognitive processes, 
memory, myasthenia gravis, and glaucoma and as an antidote to various toxins [6]. From the literature [7], 
it is known that the xanthone ring itself did not appear to automatically confer activity; in fact the 
substitution pattern has a marked influence on the activity level. Since the prepared xanthenediones 5 
are structurally related to xanthones they were evaluated for their anti-AChE activity (Table 2). The 
results showed that two derivatives are even more active than the control used, the known active 
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compound galantamine (Table 2), which is a pure competitive inhibitor of AChE used clinically in 
early stages of Alzheimer’s disease. Both active compounds present more than one hydroxyl group in 
their structure, which suggests that the presence of hydroxyl groups in the 3-aryl and 4-benzylidene 
moieties is essential for the activity. Although there are a few differences in the AChE inhibition 
assays carried out by different authors, it is possible to compare our results with those previously 
reported for xanthones. The two active compounds in the present work are much stronger inhibitors 
than those isolated from the fungus Amauroderma amoiensis, where the highest inhibition of the 
enzyme at 50 µM was only 46.3% [18]. The inhibition potencies of xanthenediones 5c and 5e is higher 
or of the same order of magnitude to those reported by a study comparing inhibition potency and 
inhibition types of six different xanthones [7]. Furthermore xanthenedione 5c has a mixed type inhibition 
of AChE, producing a combination of partially competitive and non-competitive inhibition while 
xanthenedione 5e shows an almost pure competitive type inhibition. Compounds with competitive or 
mixed inhibition of AChE are of great interest in Alzheimer’s disease therapy. Dual binding site 
inhibitors, which interact both with the catalytic and the peripheral anionic sites of the enzyme are 
particularly interesting, since they not only alleviate cognitive deficits but also behave as disease-
modifying agents by inhibiting the β-amyloid peptide aggregation [19]. 
Molecular properties such as the molecular weight, hydrophobicity (LogP), and the total polar 
surface area (TPSA) have been used extensively in modern drug discovery because they affect  
drug absorption, bioavailability, metabolism, toxicity as well as the hydrophobic drug-receptor 
interactions [20]. These and other parameters related with drug-likeness properties of xanthenediones 5 
are listed in Table 3 [21].  
Table 3. Drug-likeness property/Lipinski’s ‘rule of five’ parameters calculated for 
xanthenediones (5) a. 
Compound 
Molecular 
Weight 
miLogP n-ROTB 
n-ON 
Acceptors 
n-OHNH 
Donors 
n 
Violations 
TPSA 
5a 394.426 5.503 2 4 1 1 67.51 
5b 422.480 6.4 2 4 1 1 67.51 
5c 426.424 4.544 2 6 3 0 107.96 
5d 463.316 6.859 2 4 1 1 67.51 
5e 458.422 3.566 2 8 5 0 148.42 
5f 463.316 6.11 2 4 1 1 67.51 
a log P, octanol-water partition coefficients; n-ROTB, number of rotatable bonds; n-ON, number of hydrogen 
acceptors; n-OHNH, number of hydrogen bond donors; n violations, number of violations according to the 
Lipinski ‘rule of five’; TPSA, topological polar surface area. 
It is interesting to highlight that the xanthenediones 5e and 5c, highly active in the biological 
assays, present zero violations of Lipinski’s ‘rule of five’. On the other hand, since the TPSA 
parameter can be correlated with human intestinal absorption, the Caco-2 monolayers permeability, and 
blood-brain barrier penetration, drugs with TPSA lower than 140 Å2 and lower molecular flexibility 
(n-ROTB ≤ 6) contribute to higher intestinal permeability and higher human dose absorption [22,23]. 
Therefore, we can conclude that xanthenedione 5c combines higher AChE activity with good oral 
bioavailability properties. 
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3. Experimental 
3.1. General Information 
The 1H- and 13C-NMR, HSQC and HMBC spectra were measured in CDCl3 on Bruker Avance 300 
and 500 spectrometers (300.13 MHz and 500.13 for 1H and 75.47 and 125.75 MHz for 13C, 
respectively), using TMS as internal standard. The low-pass J-filter portion of the HMBC experiment 
was optimized for an average of one-bond heteronuclear coupling of 145 Hz; the delay for evolution of 
long-range couplings was optimized for 7 and 2 Hz. Chemical shifts were reported in δ units (ppm) 
and coupling constants (J) in Hz. The MS spectra were obtained using ESI positive mode with a  
Q-TOF 2 mass spectrometer. High resolution mass spectra (HRMS-ESI+) were performed on a 
microTOF (focus) mass spectrometer. Ions were generated using an Apollo II (ESI) source. Ionization 
was achieved by electrospray, using a voltage of 4500 V applied to the needle, and a counter voltage 
between 100 and 150 V applied to the capillary. Reactions were routinely monitored by thin-layer 
chromatography (TLC) in silica gel 60 (Merck F245 plates) and the products visualized with ultraviolet 
lamp (254 and/or 365 nm). The chromatographic purifications were carried out by CC on silica gel 60 
(70–230 mesh) and prep. TLC on silica gel (Merck silica gel 60 F254), being the spots visualized under a 
UV lamp (at 254 and/or 366 nm). 
3.2. Synthesis 
Compounds 3 and 4 were synthesised according to previously reported methodologies and the 
obtained NMR data were also identical to the data previously reported in the literature [11,12]. In the 
case of xanthenediones 5, although the synthetic methodology was previously reported only the 
characterization of derivatives 5c and 5d had been published [11]. 
(E)-3-Aryl-4-benzylidene-8-hydroxy-3,4-dihydro-1H-xanthene-1,9(2H)-dione (5a). This compound 
was obtained by the reaction of (E,E)-3-cinnamoyl-5-hydroxy-2-styrylchromone (4a, 157.8 mg,  
0.400 mmol) with BBr3 (2 mL of a 1 mol L−1 solution in CH2Cl2). After the slowly addition of BBr3 
the mixture was stirred at room temp. for 3 h, then water (80 mL) was added. The resulting reaction 
mixture was stirred for 4 h and extracted with CH2Cl2 (3 × 80 mL). The combined extracts were 
evaporated and purified by TLC using CH2Cl2 as eluent. The desired compound 5a was obtained as 
yellow crystals (107.3 mg, 68%). M.p. 216–218 °C. 1H-NMR (300 MHz, CDCl3, TMS) δ (ppm): 3.08 
(dd, 1H, J = 3.2 and 15.5 Hz, H-2trans); 3.15 (dd, 1H, J = 5.0 and 15.5 Hz, H-2cis); 4.76 (dd, 1H, J = 3.2 
and 5.0 Hz, H-3); 6.82 (dd, 1H, J = 0.7 and 8.4 Hz, H-8); 7.02 (dd, 1H, J = 0.7 and 8.4 Hz, H-6);  
7.24–7.30 (m, 3H, H-2',6' and H-4'); 7.31–7.36 (m, 2H, H-3',5'); 7.38 (br s, 5H, H-2",6", H-3",5" and 
H-4"); 7.57 (t, 1H, J = 8.4 Hz, H-7); 8.11 (s, 1H, H-7"); 12.63 (s, 1H, 9-OH). 13C-NMR (75 MHz, 
CDCl3, TMS) δ (ppm): 40.1 (C-3); 45.6 (C-2); 106.8 (C-6); 111.0 (C-9a); 112.7 (C-8); 113.4 (C-10a); 
126.9 (C-2' and C-6'); 127.5 (C-4'); 128.9 (C-3" and C-5"); 129.2 (C-3' and C-5'); 129.5 (C-2" and  
C-6"); 129.7 (C-4); 129.9 (C-4"); 134.2 (C-1"); 136.0 (C-7); 139.0 (C-7"); 139.9 (C-1'); 154.7 (C-5a); 
161.7 (C-9); 169.4 (C-4a); 180.1 (C-10); 191.3 (C-1). ESI-MS m/z 395 [M+H]+; 417 [M+Na]+; 433 
[M+K]+. HR-ESIMS (positive ion): m/z calcd. for C26H19O4 [M+H]+, 395.1278; found, 395.1275. 
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(E)-8-Hydroxy-4-(4-methylbenzylidene)-3-(4-methylphenyl)-3,4-dihydro-1H-xanthene-1,9(2H)-dione (5b). 
This compound was obtained by the reaction of (E,E)-3-cinnamoyl-5-hydroxy-2-styrylchromone (4b, 
172.8 mg, 0.409 mmol) with BBr3 (2 mL of a 1 mol L solution in CH2Cl2) and following the above 
described procedure. The desired compound 5b was obtained as yellow crystals (153.8 mg, 89%). M.p. 
201–202 °C. 1H-NMR (300 MHz, CDCl3, TMS) δ (ppm): 2.29 (s, 3H, 4'-CH3); 2.37 (s, 3H, 4"-CH3); 
3.05 (dd, 1H, J = 3.1 and 15.5 Hz, H-2trans); 3.12 (dd, 1H, J = 5.1 and 15.5 Hz, H-2cis); 4.74–4.76 (m, 
1H, H-3); 6.82 (dd, 1H, J = 0.8 and 8.3 Hz, H-8); 7.02 (dd, 1H, J = 0.8 and 8.3 Hz, H-6); 7.10 (d, 2H,  
J = 8.0 Hz, H-3',5'); 7.13 (d, 1H, J = 8.0 Hz, H-2',6'); 7.18 (d, 2H, J = 8.1 Hz, H-3",5"); 7.29 (d, 2H,  
J = 8.1 Hz, H-2",6"); 7.56 (t, 1H, J = 8.3 Hz, H-7); 8.07 (s, 1H, H-7"); 12.67 (s, 1H, 9-OH). 13C-NMR 
(75 MHz, CDCl3, TMS) δ (ppm): 20.9 (4'-CH3); 21.4 (4"-CH3); 39.9 (C-3); 45.6 (C-2); 106.8 (C-6); 
111.0 (C-9a); 112.6 (C-8); 113.3 (C-10a); 126.8 (C-2' and C-6'); 129.0 (C-4); 129.6 (C-3" and C-5"); 
129.7 (C-3' and C-5'); 129.9 (C-2" and C-6"); 131.4 (C-1"); 135.9 (C-7); 136.8 (C-1'); 137.1 (C-4'); 
139.0 (C-7"); 140.5 (C-4"); 154.7 (C-5a); 161.7 (C-9); 169.7 (C-4a); 180.2 (C-10); 191.5 (C-1). ESI-
MS m/z 423 [M+H]+; 445 [M+Na]+. HR-ESIMS (positive ion): m/z calcd. for C28H22O4 [M]+, 
423.1591; found, 423.1587. 
(E)-8-Hydroxy-4-(3,4-dihydroxybenzylidene)-3-(3,4-dihydroxyphenyl)-3,4-dihydro-1H-xanthene-1,9-
(2H)-dione (5e). This compound was obtained by the reaction of (E,E)-3-cinnamoyl-5-hydroxy-2-
styrylchromone (4e, 205.8 mg, 0.400 mmol) with BBr3 (2 mL of a 1 mol L−1 solution in CH2Cl2) and 
following the above described procedure. The desired compound 5e was filtered off and obtained as 
orange crystals (183.2 mg, 89%). M.p. 275–281 °C. 1H-NMR (500 MHz, DMSO-d6, TMS) δ (ppm): 
2.68 (dd, 1H, J = 2.7 and 14.8 Hz, H-2trans); 3.16 (dd, 1H, J = 5.7 and 14.8 Hz, H-2cis); 4.60 (dbr, 1H,  
J = 2.7 Hz, H-3); 6.57 (dd, 1H, J = 2.3 and 8.2 Hz, H-6'); 6.67 (d, 1H, J = 2.3 Hz, H-2'); 6.67 (d, 1H,  
J = 8.2 Hz, H-5');6.77 (d, 1H, J = 8.3 Hz, H-5"); 6.83 (d, 1H, J = 8.3 Hz, H-8); 6.87 (dd, 1H, J = 1.8 
and 8.3 Hz, H-6"); 6.97 (d, 1H, J = 1.8 Hz, H-2"); 7.29 (d, 1H, J = 8.3 Hz, H-6); 7.71 (t, 1H, J = 8.3 Hz, 
H-7); 8.05 (s, 1H, H-7"); 8.87 (s, 1H, 4'-OH); 8.91 (s, 1H, 3'-OH); 9.19 (s, 1H, 3"-OH); 9.84 (s, 1H, 
4"-OH); 12.77 (s, 1H, 9-OH). 13C-NMR (75 MHz, DMSO-d6, TMS) δ (ppm): 39.3 (C-3); 46.2 (C-2); 
107.8 (C-6); 110.3 (C-9a); 111.9 (C-8); 112.4 (C-10a); 114.3 (C-2'); 115.8 (C-5'); 116.1 (C-5"); 117.9 
(C-6' and C-2"); 123.5 (C-6"); 125.9 (C-4*); 126.0 (C-1"*); 131.4 (C-1'); 136.4 (C-7); 139.4 (C-7"); 
144.3 (C-3'); 145.4 (C-4'**); 145.5 (C-3"**); 148.3 (C-4"); 154.5 (C-5a); 160.7 (C-9); 169.9 (C-4a); 
179.7 (C-10); 191.4 (C-1). *It may be interchanged. **It may be interchanged. ESI-MS m/z 459 
[M+H]+; 481 [M+Na]+. HR-ESIMS (positive ion): m/z calcd. for C26H18O8 [M]+, 458.1002;  
found, 458.1003. 
(E)-4-(2-Chlorobenzylidene)-3-(2-chlorophenyl)-8-hydroxy-3,4-dihydro-1H-xanthene-1,9(2H)-dione 
(5f). This compound was obtained by the reaction of (E,E)-3-cinnamoyl-5-hydroxy-2-styrylchromone 
4f (185.8 mg, 0.401 mmol) with BBr3 (2 mL of a 1 mol L−1 solution in CH2Cl2) and following the 
above described procedure. The desired compound 5f was obtained as yellow crystals (100.3 mg, 
54%). D.p. 242 °C. 1H-NMR (300 MHz, CDCl3, TMS) δ (ppm): 2.97 (dd, 1H, J = 2.2 and 15.4 Hz,  
H-2trans); 3.11 (dd, 1H, J = 6.6 and 15.4 Hz, H-2cis); 4.91 (dd, 1H, J = 2.2 and 6.6 Hz, H-3); 6.82 (br d, 
1H, J = 7.8 Hz, H-6"); 6.89 (br d, 1H, J = 8.2 Hz, H-8); 7.09 (br d, 1H, J = 8.2 Hz, H-6); 7.10–7.14 (m, 
2H, H-5' and H-5"); 7.14–7.18 (m, 1H, H-6'); 7.23 (ddd, 1H, J = 2.1, 7.1 and 7.6 Hz, H-4'); 7.32 (ddd, 
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1H, J = 1.3, 7.4 and 8.1 Hz, H-4"); 7.42 (dd, 1H, J = 1.0 and 7.6 Hz, H-3'); 7.48 (dd, 1H, J = 0.6 and 
8.1 Hz, H-3"); 7.63 (t, 1H, J = 8.2 Hz, H-7); 8.26 (s, 1H, H-7"); 12.59 (s, 1H, 9-OH). 13C-NMR  
(75 MHz, CDCl3, TMS) δ (ppm): 38.3 (C-3); 43.9 (C-2); 107.0 (C-6); 111.2 (C-9a); 113.0 (C-8); 114.1 
(C-10a); 126.9 (C-6'); 127.6 (C-5' *); 127.7 (C-5" *); 129.0 (C-6"); 129.1 (C-4'); 130.0 (C-3"); 130.2 
(C-4); 130.7 (C-3'); 131.0 (C-4"); 132.5 (C-1"); 132.9 (C-2'); 135.0 (C-2"); 136.3 (C-7); 136.5  
(C-7"); 138.7 (C-1'); 154.8 (C-5a); 161.8 (C-9); 168.7 (C-4a); 180.1 (C-10); 191.3 (C-1). * May be 
interchanged. ESI-MS m/z 463 ([M+H]+, 35Cl); 465 ([M+H]+, 35Cl, 37Cl); 485 ([M+Na]+, 35Cl); 487 
([M+Na]+, 35Cl, 37Cl); 489 ([M+Na]+, 37Cl). HR-ESIMS (positive ion): m/z calcd. for C26H1635Cl2O4 
([M]+, 35Cl), 462.0426; found, 462.0406. Calcd. for C26H1635Cl37ClO4 ([M]+, 35Cl37Cl), 464.0396; 
found, 464.0374. Calcd. for C26H1637Cl2O4 ([M]+, 37Cl), 466.0367; found, 466.0384. 
(E)-1,13-Dihydroxy-6-(2-hydroxybenzylidene)-6,7-dihydro-7,13-methanobenzo[7,8]oxocino[4,3-b]-
chromen-14(13H)-one (6). This compound was obtained by the reaction of (E,E)-3-cinnamoyl-5-
hydroxy-2-styrylchromone (4g, 181.8 mg, 0.400 mmol) with BBr3 (2 mL of a 1 mol L−1 solution in 
CH2Cl2). After the slowly addition of BBr3 the mixture was stirred at room temp. for 3 h, then water 
(80 mL) was added. The resulting reaction mixture was stirred for 4h and extracted with CH2Cl2  
(3 × 80 mL). The combined extracts were evaporated and purified by TLC using CH2Cl2 as eluent. The 
desired compound 6 was obtained as orange crystals (74.5 mg, 41%). M.p. 195–198 °C. 1H-NMR  
(300 MHz, CDCl3, TMS) δ (ppm): 2.56 (d, 2H, J = 3.1 Hz, H-2); 4.05 (t, 1H, J = 3.1 Hz, H-3); 6.57 
(dd, 1H, J = 0.8 and 8.1 Hz, H-6); 6.64 (dd, 1H, J = 0.8 and 8.1 Hz, H-8); 6.79 (br d, 1H, J = 8.0 Hz, 
H-3'); 6.85 (ddd, 1H, J = 1.1, 7.5 and 8.1 Hz, H-5'); 7.07–7.11 (m, 1H, H-4'); 7.12 (br d, 1H, J = 7.5 Hz, 
H-6'); 7.18–7.23 (m, 1H, H-5"); 7.27 (s, 1H, H-7"); 7.34 (dd, 1H, J = 1.1, 7.6 Hz, H-6"); 7.37 (t, 1H,  
J = 8.1 Hz, H-7); 7.37–7.40 (m, H, H-3"); 7.42 (m, 1H, H-4"); 13.00 (s, 1H, 9-OH). 13C-NMR  
(75 MHz, CDCl3, TMS) δ (ppm): 31.3 (C-2); 38.3 (C-3); 100.7 (C-1); 104.9 (C-10a); 107.1 (C-6); 
108.5 (C-9a); 111.0 (C-8); 116.9 (C-3"); 118.1 (C-3'); 120.2 (C-1"); 121.4 (C-5'); 122.4 (C-1'); 124.9 
(C-5"); 127.1 (C-6"); 128.0 (C-6'); 128.7 (C-4'); 129.1 (C-7"); 131.4 (C-4); 132.5 (C-4); 136.5 (C-7); 
151.4 (C-2"); 152.1 (C-2'); 156.0 (C-5a); 158.6 (4a); 162.8 (C-9); 183.2 (C-10). ESI-MS m/z 409 
[M−H2O+H]+; 431 [M−H2O+Na]+; 447 [M−H2O+Na]+. HR-ESIMS (positive ion): m/z calcd. for 
C26H19O6 [M+H]+, 427.1176; found, 427.1181; Calcd. for C26H17O5 [M-H2O+H]+, 409, 1070;  
found, 409.1072. 
6,8-Dihydroxy-13-(2-hydroxyphenyl)chromeno[4,3-c]xanthen-7(13H)-one (7). This compound was 
obtained following the above described procedure for compound 6. The desired compound 7 was 
obtained as orange crystals (5.5 mg, 3%). D.p. 242 °C. 1H-NMR (300 MHz, CDCl3, TMS) δ (ppm): 
6.43 (d, 1H, J = 1.2 and 7.9 Hz, H-6"); 6.61 (dt, 1H, J = 1.1 and 7.9 Hz, H-5"); 6.82 (dd, 2H, J = 0.8 
and 8.3 Hz, H-8 and H-6); 6.94 (dd, 1H, J = 1.0 and 8.1 Hz, H-3"); 7.01 (dd, 1H, J = 1.1 and 8.1 Hz, 
H-3'); 7.08 (dt, 1H, J = 1.1 and 7.7 Hz, H-5'); 7.14 (s, 1H, H-7"); 7.14–7.17 (m, 1H, H-4"); 7.26 (s, 1H, 
H-2); 7.25–7.30 (m, 1H, H-4'); 7.57 (t, 1H, J = 8.3 Hz, H-7); 7.74 (dd, 1H, J = 1.5 and 7.7 Hz, H-6'); 
11.80 (s, 1H, 9-OH); 12.01 (s, 1H, 1-OH). 13C-NMR (75 MHz, CDCl3, TMS) δ (ppm): 70.9 (C-7"); 
104.9 (C-2); 106.7 (C-10a); 107.4 (C-6); 107.9 (C-9a); 108.9 (C-4); 111.4 (C-8); 116.8 (C-3"); 118.0 
(C-3'); 120.2 (C-5"); 121.3 (C-1'); 123.3 (C-5' and C-1"); 124.7 (C-6'); 127.8 (C-6"); 130.5 (C-4"); 
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132.1 (C-4'); 137.6 (C-7); 139.2 (C-3); 152.0 (C-2'); 152.2 (C-4a); 155.7 (C-2"); 155.9 (C-5a); 161.4 
(C-9); 161.7 (C-1); 185.5 (C-10). ESI-MS m/z 425 [M+H]+; 447 [M+Na]+; 463 [M+K]+. 
1,8-Dihydroxy-4-(4-methylbenzyl)-3-(4-methylphenyl)-9H-xanthen-9-one (8b). This compound was 
obtained by the treatment of a solution of (E)-8-hydroxy-4-(4-methylbenzylidene)-3-(4-methylphenyl)-
3,4-dihydro-1H-xanthene-1,9(2H)-dione (5b, 56.7 mg, 0.13 mmol) in DMSO (10 mL) with DBU  
(1.2 equiv, 24 µL, 0.16 mmol). The mixture was then irradiated in an Ethos SYNTH microwave 
(Milestone Inc., Sorisole, Italy) at 100 °C for 10 min. After this period the reaction mixture was poured 
onto ice (10 g) and the pH was adjusted to 3–4 with diluted HCl and extracted with chloroform. The 
desired compound 8b was obtained by TLC purification using a mixture of hexane/CH2Cl2 (3:1) as 
eluent, as orange crystals, 18% yield (10.2 mg). M.p. 155–157 °C; 1H-NMR (300 MHz, CDCl3, TMS) 
δ (ppm): 2.26 (s, 3H, 4"-CH3); 2.40 (s, 3H, 4'-CH3); 4.10 (s, 2H, H-7"); 6.77 (dd, 1H, J = 0.7 and 8.8 Hz, 
H-8); 6.79 (s, 1H, H-2); 6.81 (dd, 1H, J = 0.7 and 8.8 Hz, H-6); 6.90 (d, 2H, J = 8.1 Hz, H-2",6"); 6.99 
(d, 2H, J = 8.1 Hz, H-3",5"); 7.17–7.19 (m, 2H, H-2',6'); 7.19–7.21 (m, 2H, H-3',5'); 7.55 (t, 1H,  
J = 8.8 Hz, H-7); 11.78 (s, 1H, 1-OH); 11.86 (s, 1H, 9-OH). 13C-NMR (75 MHz, CDCl3, TMS) δ 
(ppm): 20.9 (4"-CH3); 21.2 (4'-CH3); 31.7 (C-7"); 107.0 (C-10a); 107.2 (C-6); 107.7 (C-9a); 110.7  
(C-8); 112.5 (C-2); 117.1 (C-4*); 127.8 (C-2" and C-6"); 128.6 (C-2' and C-6'); 128.9 (C-3', C-3", C-5' 
and C-5"); 135.2 (C-4"); 137.1 (C-1') 137.3 (C-7); 137.4 (C-3*); 137.7 (C-1"); 137.9 (C-4'); 152.3  
(C-4a); 156.3 (C-5a); 158.8 (C-1); 161.2 (C-9); 186.1 (C-10). * May be interchanged. ESI-MS m/z 423 
[M+H]+; 445 [M+Na]+. HR-ESIMS (positive ion): m/z calcd. for C28H22O4 [M]+, 422.1518;  
found, 422.1520. 
1,8-Dihydroxy-4-(4-methylbenzoyl)-3-(4-methylphenyl)-9H-xanthen-9-one (9b). This compound was 
obtained by the treatment of a solution of (E)-8-hydroxy-4-(4-methylbenzylidene)-3-(4-methylphenyl)-3,4-
dihydro-1H-xanthene-1,9(2H)-dione (5b, 66.9 mg, 0.16 mmol) in 1,2,4-trichlorobenzene (TCB) (10 mL) 
with DQQ (2.0 equiv, 72.0 mg, 0.32 mmol). The mixture was then irradiated in an Ethos SYNTH 
microwave (Milestone Inc.) at 170 °C for 30 min. After this the TCB was removed by column 
chromatography using hexane as eluent and the reaction mixture was eluted with CH2Cl2. The desired 
compound 9b was obtained by TLC purification using successively hexane and CH2Cl2 as eluents, as 
yellow solid, 28% yield (19.1 mg). M.p. 180–183 °C; 1H-NMR (300 MHz, CDCl3, TMS) δ (ppm): 
2.28 (s, 3H, 4'-CH3); 2.36 (s, 3H, 4"-CH3); 2.98 (sb, 1H, 7"-OH); 6.02 (d, 1H, J = 9.0 Hz, H-7"); 6.60 
(dd, 1H, J = 0.8 and 8.4 Hz, H-6); 6.77 (dd, 1H, J = 0.8 and 8.4 Hz, H-8); 6.91 (s, 1H, H-2); 7.06 (d, 
2H, J = 8.2 Hz, H-3',5'); 7.15 (d, 2H, J = 8.2 Hz, H-3",5"); 7.22 (d, 2H, J = 8.2 Hz, H-2',6'); 7.50 (t, 
1H, J = 8.4 Hz, H-7); 7.65 '(d, 2H, J = 8.2 Hz, H-2",6"); 11.71 (s, 1H, 9-OH); 12.06 (s, 1H, 1-OH). 
13C-NMR (75 MHz, CDCl3, TMS) δ (ppm): 21.2 (4'-CH3); 21.7 (4"-CH3); 106.1 (C-10a); 107.4 (C-6); 
107.7 (C-9a); 111.1 (C-8); 112.3 (C-2); 118.6 (C-4); 128.5 (C-2' and C-6'); 129.2 (C-3', C-5', C-3" and 
C-5"); 129.6 (C-2" and C-6"); 135.4 (C-1"); 135.6 (C-1'); 137.6 (C-7); 138.7 (C-4'); 144.4 (C-4"); 
150.4 (C-3); 153.4 (C-4a); 155.9 (C-5a); 161.2 (C-9); 161.4 (C-1); 185.7 (C-10); 194.0 (C-7");. ESI-
MS m/z 437 [M+H]+, 459 [M+Na]+, 475 [M+K]+. HR-ESIMS (positive ion): m/z calcd. for C28H20O5 
[M]+, 436,1311; found, 436.1319. 
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6,8-Dihydroxy-2-methyl-13-(4-methylphenyl)indeno[1,2-c]xanthen-7(13H)-one (10b). This compound 
was obtained by the treatment of a solution of (E)-8-hydroxy-4-(4-methylbenzylidene)-3-(4-
methylphenyl)-3,4-dihydro-1H-xanthene-1,9(2H)-dione (5b, 50.5 mg, 0.12 mmol) in dry 1,2,4-
trichlorobenzene (TCB) (10 mL) and in the presence of 100 mg molecular sieves with DQQ (1.5 equiv, 
40.6 mg, 0.18 mmol). The mixture was then irradiated in an Ethos SYNTH microwave (Milestone Inc.) 
at 170 °C for 30 min. After this the TCB was removed by column chromatography using hexane as 
eluent and the reaction mixture was eluted with CH2Cl2. The desired compound 10b was obtained by 
TLC purification using a mixture of hexane/CH2Cl2 (3:2) as eluent, as yellow crystals, 52% yield  
(26.0 mg). D.p. 195 °C; 1H-NMR (300 MHz, CDCl3, TMS) δ (ppm): 2.28 (s, 3H, 4"-CH3); 2.36 (s, 3H, 
4'-CH3); 5.14 (s, 1H, H-7"); 6.64 (dd, 1H, J = 0.7 and 8.3 Hz, H-6); 6.70 (dd, 1H, J = 0.7 and 8.3 Hz, 
H-8); 7.01 (d, 2H, J = 8.2 Hz, H-2",6"); 7.06 (d, 2H, J = 8.2 Hz, H-3",5"); 7.13 (br s, 1H, H-3'); 7.14  
(s, 1H, H-2); 7.20 (br d, 1H, J = 7.9 Hz, H-5'); 7.47 (t, 1H, J = 8.3 Hz, H-7); 7.67 (d, 1H, J = 7.9 Hz, 
H-6'); 11.90 (s, 1H, 9-OH); 12.05 (s, 1H, 1-OH). 13C-NMR (75 MHz, CDCl3, TMS) δ (ppm): 21.1  
(4"-CH3); 21.8 (4'-CH3); 51.5 (C-7"); 102.1 (C-2); 106.4 (C-10a); 106.9 (C-6); 107.8 (C-9a); 110.7  
(C-8); 121.1 (C-6'); 123.3 (C-4); 126.1 (C-3'); 128.0 (C-2" and C-6"); 128.6 (C- 5'); 129.2 (C-3" and 
C-5"); 136.4 (C-4"); 136.8 (C-1"*); 136.9 (C-7); 137.0 (C-1'*); 140.3 (C-4'); 150.7 (C-2'); 151.4  
(C-4a); 152.0 (C-3); 155.9 (C-5a); 161.3 (C-9); 162.2 (C-1); 185.5 (C-10) * May be interchanged.  
ESI-MS m/z 421 [M+H]+; 443 [M+Na]+, 459 [M+K]+. HR-ESIMS (positive ion): m/z calcd. for 
C28H20O4 [M]+, 420.1362; found, 420.1364. 
1,8-Dihydroxy-4-[(4-methylphenyl)hydroxymethyl]-3-(4-methylphenyl)-9H-xanthen-9-one (11b). This 
compound was obtained by the treatment of a solution of (E)-8-hydroxy-4-(4-methylbenzylidene)-3-
(4-methylphenyl)-3,4-dihydro-1H-xanthene-1,9(2H)-dione (5b, 58.8 mg, 0.14 mmol) in dried 1,2,4-
trichlorobenzene (TCB) (10 mL) and in the presence of 100 mg molecular sieves with DQQ (1.3 equiv, 
42.0 mg, 0.18 mmol). The mixture was then irradiated in an Ethos SYNTH microwave (Milestone Inc.) 
at 100 °C for 30 min. After this the TCB was removed by column chromatography using hexane as 
eluent and the reaction mixture was eluted with CH2Cl2. The desired compound 11b was obtained by 
TLC purification using a mixture of hexane/CH2Cl2 (3:2) as eluent, as yellow crystals, 30% yield 
(18.6 mg). M.p. 134–136 °C; 1H-NMR (300 MHz, CDCl3, TMS) δ (ppm): 2.29 (s, 3H, 4"-CH3); 2.39 
(s, 3H, 4'-CH3); 6.02 (d, 1H, J = 9.0 Hz, H-7"); 6.55 (br d, 1H, J = 8.2 Hz, H-6); 6.74 (dd, 1H, J = 0.7 and 
8.2 Hz, H-8); 6.79 (s, 1H, H-2); 7.07 (d, 2H, J = 8.0 Hz, H-3",5"); 7.17 (d, 2H, J = 8.0 Hz, H-2",6"); 
7.22 (d, 2H, J = 8.1 Hz, H-3',5'); 7.28 (d, 2H, J = 8.1 Hz, H-2',6'); 7.48 (t, 1H, J = 8.2 Hz, H-7); 11.70 
(s, 1H, 9-OH); 11.84 (s, 1H, 1-OH). 13C-NMR (75 MHz, CDCl3, TMS) δ (ppm): 21.0 (4"-CH3); 21.2 
(4'-CH3); 70.8 (C-7"); 106.7 (C-6); 107.4 (C-10a); 107.6 (C-9a); 111.1 (C-8); 112.6 (C-2); 119.5 (C-4); 
125.1 (C-2" and C-6"); 128.6 (C-2' and C-6'); 128.8 (C-3" and C-5"); 129.2 (C-3' and C-5'); 136.4 (C-1' 
and C-4"); 137.4 (C-7); 138.3 (C-4'); 140.8 (C-1"); 151.9 (C-3); 154.6 (C-4a); 155.5 (C-5a); 159.8 (C-1); 
161.2 (C-9); 185.8 (C-10). ESI-MS m/z 421 [M−18+H]+, 443 [M−18+Na]+, 459 [M−18+K]+. HR-ESIMS 
(positive ion): m/z calcd. for C28H20O5 [M]+, 438,1467; found, 438.1477. 
6,8,13-Trihydroxy-2-methyl-13-(4-methyphenyl)indeno[1,2-c]xanthen-7(13H)-one (12b). This 
compound was obtained by the treatment of a solution of (E)-8-hydroxy-4-(4-methylbenzylidene)-3-
(4-methylphenyl)-3,4-dihydro-1H-xanthene-1,9(2H)-dione (5b, 57.6 mg, 0.14 mmol) in dried 1,24-
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trichlorobenzene (TCB) (10 mL) and in the presence of 100 mg molecular sieves with chloranil  
(2.0 equiv, 68.0 mg, 0.28 mmol). The mixture was then irradiated in an Ethos SYNTH microwave 
(Milestone Inc.) at 170 °C for 30 min. After this the TCB was removed by column chromatography 
using hexane as eluent and a semi-purified fraction was eluted with CH2Cl2. The desired compound 
12b was obtained by TLC purification using a mixture of hexane/CH2Cl2 (3:2) as eluent, as yellow 
crystals, 34% yield (20.7 mg). D.p. 145 °C; 1H-NMR (300 MHz, CDCl3, TMS) δ (ppm): 2.29 (s, 3H, 
4"-CH3); 2.35 (s, 3H, 4'-CH3); 6.70 (dd, 1H, J = 0.8 and 8.3 Hz, H-6); 6.73 (dd, 1H, J = 0.8 and 8.3 Hz, 
H-8); 7.07 (s, 1H, H-2); 7.08 (d, 2H, J = 8.4 Hz, H-3",5"); 7.18 (d, 1H, J = 0.9 Hz, H-3'); 7.20–7.23 
(m, 1H, H-5'); 7.33 (d, 2H, J = 8.4 Hz, H-2",6"); 7.50 (t, 1H, J = 8.3 Hz, H-7); 7.58 (d, 1H, J = 7.7 Hz,  
H-6'); 11.81 (s, 1H, 9-OH); 12.22 (s, 1H, 1-OH). 13C-NMR (75 MHz, CDCl3, TMS) δ (ppm): 21.1  
(4"-CH3); 21.8 (4'-CH3); 83.1 (C-7"); 102.5 (C-2); 106.7 (C-10a); 107.2 (C-6); 107.6 (C-9a); 111.0  
(C-8); 121.3 (C-6'); 125.1 (C-3', C-2" and C-6"); 128.9 (C-3" and C-5"); 130.1 (C-5'); 134.9 (C-1'); 
137.0 (C-4"); 137.1 (C-7); 139.0 (C-4 and C-1"); 141.5 (C-4'); 150.2 (C-3 *); 151.5 (C-4a); 152.8 (C-2' *); 
155.8 (C-5a); 161.2 (C-9); 163.7 (C-1); 185.3 (C-10) *May be interchanged. ESI-MS m/z 459 [M+Na]+. 
HR-ESIMS (positive ion): m/z calcd. for C28H21O5 [M+H]+, 437.1384; found, 437.1380. 
3.3. Determination of the Reducing Power 
The reductive potential of the compounds and standard was determined according to a previously 
described method [17]. An aliquot of the sample or standard (1.0 mL) at various concentrations  
(20–80 μg/mL in DMSO) was mixed with phosphate buffer (0.2 mol L−1, pH 6.6, 1.25 mL) and 1% 
potassium ferricyanide (1.25 mL). The mixture was incubated at 50 °C for 20 min. After cooling,  
1.25 mL of 10% trichloroacetic acid was added and the mixture incubated at 50 °C for 10 min.  
1.25 mL of this solution was mixed with distilled water (1.25 mL) and 0.1% iron(III) chloride  
(0.25 mL) and the absorbance measured at 700 nm using an appropriate blank. Assays were carried out 
in triplicate. 
3.4. DPPH Radical Scavenging Assay 
Antioxidant activity was assayed by the DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging 
assay using the Blois method modified [24]. Briefly, different volumes of the ethanolic solutions of 
each compound or standard (1–100 µM) were added fixed volume of DPPH ethanolic solution (400 µL 
of the solution 0.6 mM) and solvent (ethanol) to obtain, in each case, a fixed total volume. In each 
assay, a control was prepared, in which the compound or standard (quercetin and BHT) was substituted 
by the same amount of solvent. The mixture was shaken vigorously and left to stand for 30 min in the 
dark, and the absorbance was then measured at 517 nm. The capability to scavenge the DPPH radical 
was calculated using the following equation:  
DPPH scavenging activity (%) = [(Ac − As)/Ac] × 100 (1)
where, Ac is the absorbance of the control and As is the absorbance of the compound or standard. All 
assays were carried out in triplicate and results expressed as EC50, i.e., as the concentration yielding 
50% scavenging of DPPH, calculated by interpolation from the % vs. concentration curve. 
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3.5. Microplate Assay for AChE Activity 
The AChE activity was evaluated using the method described by Ellman et al. [25] and  
Ingkaninan et al. [26], modified. Briefly, 10 μL of 0.25 U/mL AChE from Electrophorus electricus 
(Sigma-Aldrich® Chemical Company, St. Louis, MO, USA) was added to the wells containing sample 
in different concentrations, and allowed to incubate for 5 min. Reaction was started by the addition  
5 μL of 3 mM 5,5'-dithiobis[2-nitrobenzoic acid] (DTNB,) and 5 μL of 75 mM acetylthiocholine 
iodide (ATCI; Fluka Chemicals, Buchs, Switzerland). The absorbance was then read at 415 nm  
every 2.5 min for 7.5 min in a Bio Rad Model 680 Microplate Reader (Bio-Rad Laboratories, Inc., 
Hercules, CA, USA). Percentage of enzymatic inhibition was calculated relatively to the control 
without inhibitor. Every experiment was done in quadruplicate. To determine IC50 values, EPA 
PROBIT ANALYSIS PROGRAM Version 1.4 was used. 
4. Conclusions 
In conclusion, (E)-3-aryl-4-benzylidene-8-hydroxy-3,4-dihydro-1H-xanthene-1,9(2H)-diones 5 can 
be successfully obtained by simple and efficient methodologies from (E,E)-3-cinnamoyl-5-hydroxy-2-
styrylchromones 4. These compounds seem to be good synthons towards new interesting xanthone 
derivatives and, with the appropriate substitution patterns, powerful antioxidants and AChEI.  
The combination of these activities and the inhibition type displayed by these compounds suggest  
that they may be the excellent templates for drugs to be used in the prevention and treatment of 
neurodegenerative diseases. 
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